KORU Medical Systems, Inc. (KRMD)

KORU Medical Systems experienced several notable events impacting its stock price in the past six months. The company reported Q3 2025 revenue exceeding $10 million, leading to a stock increase. Full-year revenue guidance for 2025 was raised to $40.5-$41 million. KORU Medical received FDA clearance for its infusion system to be used with UCB's RYSTIGGO therapy and submitted a 510(k) premarket notification to the FDA for an oncology market entry device. Preliminary Q4 2025 net revenues were reported at $10.9 million. Analysts have given KORU Medical Systems a consensus rating of "Moderate Buy" or "Strong Buy".

KORU Medical Systems' core business is largely driven by recurring revenues from products used for chronic conditions, suggesting a relatively stable demand pattern for its primary products rather than significant seasonality.

KORU Medical Systems, Inc. is a medical technology company focused on developing, manufacturing, and commercializing subcutaneous infusion solutions, particularly the FREEDOM Infusion Systems. These systems are designed for delivering life-saving immunoglobulin therapies to patients with chronic illnesses. The company operates in the Healthcare sector, specifically within the Medical Devices and Supplies industry. Its major products include the Freedom Integrated Infusion System, which facilitates self-administration of large-volume subcutaneous drugs in home and alternate care settings.

KORU Medical Systems, Inc. develops, manufactures, and commercializes its subcutaneous infusion solutions in the United States and internationally. The company's corporate headquarters are located in Mahwah, New Jersey. International revenue has shown significant growth, with a surge of 230% year-over-year reported in Q3 2025, contributing to the company's overall expansion.

KORU Medical Systems has demonstrated positive developments for its brand reputation in the past year. The company announced a successful appeal related to an ongoing audit by its EU notified body, ensuring continued product sales in the EU. The company's strong financial performance also contributes positively to its brand perception.

KORU Medical Systems, Inc. has a concentrated ownership structure, with insiders holding a significant stake. The company has 141 institutional owners and shareholders, holding a total of 22,110,065 shares. Major institutional owners include First Light Asset Management, LLC, Topline Capital Management, LLC, Vanguard Group Inc, BlackRock, Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Geode Capital Management, Llc, Meros Investment Management, LP, Empire Financial Management Company, LLC, Acuitas Investments, LLC, and IWM - iShares Russell 2000 ETF. Insiders collectively hold approximately 46.16% of the shares, with institutional investors holding around 42.13%.